WellDoc®, a health care behavioral science and technology company that develops mHealth solutions aimed at engaging patients and enhancing health outcomes, is focused on empowering people and providers to radically transform and improve how they manage chronic conditions and improve health outcomes. WellDoc has introduced BlueStar®, the first Mobile Prescription Therapy cleared by the FDA for adults with type 2 diabetes. BlueStar is an industry-leading, technology-based prescription solution designed to help people better manage their condition in-between office visits and help providers understand self-management trends and patterns at the office visit. Forbes selected WellDoc as one of “America's Most Promising Companies” based on its potential for future growth, and in January 2014, WellDoc closed a $20 million Series A led by the Merck Global Health Innovation Fund. For more information, visit www.WellDoc.com and www.BlueStarDiabetes.com.